Early Development and Discovery Sciences, Merck and Co., Inc. , 2000 Galloping Hill Road, Kenilworth, New Jersey 07033, United States.
J Med Chem. 2014 Feb 27;57(4):1437-53. doi: 10.1021/jm4017224. Epub 2014 Feb 5.
A series of conformationally restricted acetanilides were synthesized and evaluated as β3-adrenergic receptor agonists (β3-AR) for the treatment of overactive bladder (OAB). Optimization studies identified a five-membered ring as the preferred conformational lock of the acetanilide. Further optimization of both the aromatic and thiazole regions led to compounds such as 19 and 29, which have a good balance of potency and selectivity. These compounds have significantly reduced intrinsic clearance compared to our initial series of pyridylethanolamine β3-AR agonists and thus have improved unbound drug exposures. Both analogues demonstrated dose dependent β3-AR mediated responses in a rat bladder hyperactivity model.
一系列构象受限的乙酰苯胺类化合物被合成并评估为β3-肾上腺素能受体激动剂(β3-AR),用于治疗膀胱过度活动症(OAB)。优化研究确定五元环为乙酰苯胺的首选构象锁。对芳基和噻唑区域的进一步优化导致了化合物 19 和 29 的产生,它们具有良好的效力和选择性平衡。与我们最初的一系列吡啶乙醇胺β3-AR 激动剂相比,这些化合物的内在清除率显著降低,因此具有改善的游离药物暴露。两种类似物在大鼠膀胱过度活动模型中均表现出剂量依赖性的β3-AR 介导的反应。